Zevra Sells ADHD and Sleep Disorder Assets for $50 Million, Focuses on Rare Diseases

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) announced on March 16 that it has agreed to sell its serdexmethylphenidate (SDX) portfolio, the ADHD treatment AZSTARYS and sleep-disorder candidate KP1077 to Commave Therapeutics SA for $50 million (approximately KRW 70 billion), while simultaneously resolving all related litigation in the Delaware Court of Chancery. Prior to closing the deal, Zevra repaid its outstanding $63 million (approximately KRW 90 billion) debt in full, creating a debt-free capital structure and enabling the company to concentrate its resources on developing and commercializing its rare-disease pipeline.

Earlier, in September 2024 Zevra secured U.S. FDA approval for MIPLYFFA (arimoclomol) to treat Niemann-Pick disease type C and has since launched U.S. sales. The company has been broadening its rare-disease portfolio to include Olpruva and Seliprolol. According to recent SEC filings and corporate presentations, Zevra is pursuing a strategy that builds revenue around its commercial-stage assets while advancing a late-stage rare-disease pipeline.

Zevra is a Nasdaq-listed, U.S. commercial-stage biotech specializing in rare diseases such as Niemann-Pick disease type C, urea cycle disorders and vascular Ehlers-Danlos syndrome. Although the global market for rare-disease therapies serves a small patient population, limited treatment options, high pricing and expedited regulatory pathways continue to attract specialized biotechs focused on a select number of promising programs.